Home Current Issue Previous Issues Epub Ahead Reports CME Podcasts Grand Rounds For Authors Journal Info
Skip Navigation LinksHome > October 2012 - Volume 73 - Issue 4 > New anticoagulants: A concise review
Journal of Trauma and Acute Care Surgery:
doi: 10.1097/TA.0b013e318265cf9e
Review Articles

New anticoagulants: A concise review

Baumann Kreuziger, Lisa M. MD; Morton, Colleen T. MBBS; Dries, David J. MSE; MD

Editor's Choice
Collapse Box

Abstract

Abstract: During the last 2 years, two new oral anticoagulants, dabigatran and rivaroxaban, have been approved in the United States. Phase II and Phase III clinical trials of dabigatran, rivaroxaban, and apixaban are summarized. Approach to perioperative management depends on the half-life of the medication, risk of surgical bleeding, and the patient’s renal function. No reversal agent is available for any of the new oral anticoagulants. Management of bleeding patients is based on local measures and consideration of antifibrinolytic therapy and activated factor VII or prothrombin complex concentrate infusion based on healthy volunteer and animal studies. The new oral anticoagulants provide additional options to prevent venous thromboembolism in patients after orthopedic surgery or stroke in patients with atrial fibrillation but present unique challenges compared to warfarin.

© 2012 Lippincott Williams & Wilkins, Inc.

Follow Us


Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.